Current Edition

Unlocking the Biomarker Revolution in Clinical Trials

Completion of the first human genome sequence exactly 20 years ago opened up the tantalising prospect of a new era of precision treatments, with accurate genetic diagnosis enabling therapies to be targeted to smaller subsets of patients, increasing the chances of success and reducing side-effects. Barnaby Balmforth at Biofidelity Ltd explains the real value of diagnostics and their absolutely critical role in delivering the benefits of biomarkers in healthcare.